Browse RIMS1

Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Peripheral membrane protein Cell junction, synapse Cell junction, synapse, presynaptic cell membrane Peripheral membrane protein
Domain PF00168 C2 domain
PF00595 PDZ domain (Also known as DHR or GLGF)
Function

Rab effector involved in exocytosis (By similarity). May act as scaffold protein that regulates neurotransmitter release at the active zone. Essential for maintaining normal probability of neurotransmitter release and for regulating release during short-term synaptic plasticity (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003).

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0001558 regulation of cell growth
GO:0006820 anion transport
GO:0006835 dicarboxylic acid transport
GO:0006836 neurotransmitter transport
GO:0006887 exocytosis
GO:0007269 neurotransmitter secretion
GO:0007601 visual perception
GO:0010720 positive regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014047 glutamate secretion
GO:0015711 organic anion transport
GO:0016049 cell growth
GO:0016079 synaptic vesicle exocytosis
GO:0017156 calcium ion regulated exocytosis
GO:0017157 regulation of exocytosis
GO:0017158 regulation of calcium ion-dependent exocytosis
GO:0022604 regulation of cell morphogenesis
GO:0023061 signal release
GO:0030307 positive regulation of cell growth
GO:0031346 positive regulation of cell projection organization
GO:0042391 regulation of membrane potential
GO:0045055 regulated exocytosis
GO:0045666 positive regulation of neuron differentiation
GO:0045927 positive regulation of growth
GO:0046928 regulation of neurotransmitter secretion
GO:0046942 carboxylic acid transport
GO:0048489 synaptic vesicle transport
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048791 calcium ion-regulated exocytosis of neurotransmitter
GO:0050769 positive regulation of neurogenesis
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050953 sensory perception of light stimulus
GO:0051588 regulation of neurotransmitter transport
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0051962 positive regulation of nervous system development
GO:0060078 regulation of postsynaptic membrane potential
GO:0060079 excitatory postsynaptic potential
GO:0060080 inhibitory postsynaptic potential
GO:0060560 developmental growth involved in morphogenesis
GO:0060627 regulation of vesicle-mediated transport
GO:0061025 membrane fusion
GO:0097151 positive regulation of inhibitory postsynaptic potential
GO:0097479 synaptic vesicle localization
GO:0097480 establishment of synaptic vesicle localization
GO:0097484 dendrite extension
GO:0098815 modulation of excitatory postsynaptic potential
GO:0098828 modulation of inhibitory postsynaptic potential
GO:0099003 vesicle-mediated transport in synapse
GO:0099504 synaptic vesicle cycle
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099565 chemical synaptic transmission, postsynaptic
GO:0099643 signal release from synapse
GO:1902803 regulation of synaptic vesicle transport
GO:1903305 regulation of regulated secretory pathway
GO:1903859 regulation of dendrite extension
GO:1903861 positive regulation of dendrite extension
GO:1990138 neuron projection extension
GO:2000300 regulation of synaptic vesicle exocytosis
GO:2000463 positive regulation of excitatory postsynaptic potential
Molecular Function GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0030695 GTPase regulator activity
GO:0031267 small GTPase binding
GO:0044325 ion channel binding
GO:0051020 GTPase binding
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0042734 presynaptic membrane
GO:0048786 presynaptic active zone
GO:0097060 synaptic membrane
GO:0098793 presynapse
> KEGG and Reactome Pathway
 
KEGG hsa04721 Synaptic vesicle cycle
hsa04723 Retrograde endocannabinoid signaling
Reactome R-HSA-264642: Acetylcholine Neurotransmitter Release Cycle
R-HSA-212676: Dopamine Neurotransmitter Release Cycle
R-HSA-888590: GABA synthesis, release, reuptake and degradation
R-HSA-210500: Glutamate Neurotransmitter Release Cycle
R-HSA-112316: Neuronal System
R-HSA-112310: Neurotransmitter Release Cycle
R-HSA-181430: Norepinephrine Neurotransmitter Release Cycle
R-HSA-181429: Serotonin Neurotransmitter Release Cycle
R-HSA-112315: Transmission across Chemical Synapses
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RIMS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RIMS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RIMS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2230.659
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.360.818
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.040.981
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5380.445
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3660.798
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8690.608
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2270.635
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2270.745
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3720.242
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RIMS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.111.8-4.71
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414257.117.90.405
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277325.96.819.10.0153
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275925.98.517.40.0441
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171935.3-16.30.293
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86033.3-33.30.165
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.836.4-5.61
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.115.4-6.30.618
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RIMS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RIMS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RIMS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RIMS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RIMS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RIMS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRIMS1
Nameregulating synaptic membrane exocytosis 1
Aliases KIAA0340; RIM1; Rab3-interacting molecule; RAB3IP2; CORD7; RAB3 interacting protein 2; RAB3-interacting prot ......
Chromosomal Location6q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RIMS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.